Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O’Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27;392(9):875-891. doi: 10.1056/NEJMoa2411680. Epub 2024 Dec 7. PMID: 39651791; PMCID: PMC11864901.
Study ID Citation
Abstract
B-lymphoblastic leukemia (B-ALL) is the most common childhood cancer. Despite high overall cure rates, relapsed B-ALL remains a leading cause of cancer death among children. Adding the bispecific T-cell engager blinatumomab (CD19xCD3) to therapy for newly diagnosed NCI standard risk (SR) pediatric B-ALL may improve outcomes. AALL1731 is a phase 3 trial that randomized children with newly diagnosed SR B-ALL of average (SR-Avg) and higher (SR-High) relapse risk to chemotherapy or chemotherapy plus two non-sequential 28-day blinatumomab cycles. The primary endpoint was disease-free survival.